sameAs
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisPharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implicationsAnalyzing mHealth Engagement: Joint Models for Intensively Collected User Engagement Data.Cost of antipsychotic polypharmacy in the treatment of schizophrenia.The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital DischargeEvaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysisLack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionalityAkathisia: an updated review focusing on second-generation antipsychotics.Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension studyAssessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatryCardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.The Mount Sinai conference on the pharmacotherapy of schizophrenia.Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia.Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.Treatment models and designs for intervention research during the psychotic prodrome.Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysisPatterns of stress in schizophrenia.Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.The genetics of symptom-based phenotypes: toward a molecular classification of schizophreniaAntipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes.Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trialsNon-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia.Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis.White matter changes associated with antipsychotic treatment in first-episode psychosis.Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients.Schizophrenia: mechanism of action of current and novel treatments.A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial.
P50
Q24606868-450A1031-1D2C-455B-BE18-322F04CFDF11Q28295134-B2B2223A-7C3B-47F6-B3B1-156738928015Q31154469-A1CF7C36-A2D8-4541-B48B-7EAA08004BEDQ33327172-255D814B-7F35-4C02-B6D3-B9ABCA2E77E6Q33369362-E74A8A42-8A98-452E-91D9-4E930E236486Q33389158-153B5891-7F2B-40A7-8F8A-2DC080F56221Q33449911-AB1853DB-C39D-49BF-9652-4853D1F49D97Q33518314-8FA45974-E2C0-48FC-9612-9E3F65E9F157Q33566832-88AD53DD-DCE5-4BEB-8635-3494FB6BC7BFQ33694959-070A02EC-13D2-48DA-82B0-F195248DF6CEQ34017194-2C77F1C0-835F-4275-866B-7E60755205CAQ34112064-79BE1BF4-914B-47D9-8774-575C8F013E12Q34357174-D27D1BA3-2DBA-446E-B90C-198BEB9FFDB0Q34613195-15C09460-C2C3-4861-9CA8-6C603156EF0AQ34660736-17A86E44-F610-41D5-B485-35B318DE9EC3Q34669153-38627DB0-0DC0-4373-AD2D-F1E8BC45DC78Q34861424-12671C62-C22D-499C-A64B-673A8E63995CQ34985997-EFC9A529-8AD8-4686-A920-4D86F3D9BEB8Q35042829-DB789089-9718-46B7-BAA6-B13719190991Q35593695-80B1EDFB-FC03-46D3-9097-211C12DB91E7Q35677886-006D687C-94B6-4662-8B50-84C3BC550079Q36550998-B9BDC0BF-EC46-41D6-822C-7EFDA4100DDBQ36796042-D32D123F-76F9-4037-AA04-72663127D5F4Q37007725-046B6513-016D-404F-8DC2-541CC65F14D3Q37076517-BE2A2ECD-0817-4EAF-B5B2-CF08A25D6A5DQ37137001-5A05785B-54F9-490F-9B83-A8AFD47B28E0Q37149314-A54A445E-EF7A-4A74-9AFF-577003ECAFB0Q37155942-9AE1D3BE-2993-4479-9EF7-B2E69C774FC9Q37216848-A38A08EA-C457-480B-A7CD-09EB904BBBCCQ37228346-1DC5E418-5B34-45AC-B8EA-796373FF697BQ37236148-3D69AE95-0E86-4C41-B32C-1C07DBEEACB8Q37425212-8C816A5C-FEF6-4B51-9E45-AA00D8C74F76Q37624223-62F5544A-897D-4A54-BCA5-D6CDB7A38B50Q37705723-F3992FB5-2B3D-4B07-9ACD-AEF1B0A0D93EQ38202393-614EAEB9-DE4D-47B8-B1E6-ED306FB870A9Q38210597-28F6A478-BD8C-44C2-BA01-47C4292EDA02Q38377724-FCAE3A6D-17C8-44E4-A2CC-F90A3842568FQ38382821-89A7641C-12A0-47FD-A4D9-4AB39242B246Q38424199-1D1FB5B7-3DFD-4FD2-9058-74CEBEA68475Q38432506-6537FC7F-4343-4DC4-943E-E1DDF233C836
P50
description
psychiater
@nl
researcher
@en
հետազոտող
@hy
name
John M. Kane
@ast
John M. Kane
@en
John M. Kane
@es
John M. Kane
@nl
type
label
John M. Kane
@ast
John M. Kane
@en
John M. Kane
@es
John M. Kane
@nl
altLabel
John M Kane
@ast
John M Kane
@en
John M Kane
@es
John M Kane
@nl
prefLabel
John M. Kane
@ast
John M. Kane
@en
John M. Kane
@es
John M. Kane
@nl
P21
P31
P496
0000-0002-2628-9442